Latest filing published 21 Jun 2022 for Chemomab Therapeutics Ltd., €752.
Filing timeline
BuySaleInsider track record
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Donald Marvin: trading record in brief
Donald Marvin, listed as finance chief, appears in our data through filings on Chemomab Therapeutics Ltd. shares, published by SEC (Form 4). The record holds 7 filings, for trades running from 14 March 2022 to 16 March 2022.
Purchases make up the whole of the open-market record (7 purchases, €6,108). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The median purchase comes to €910. On 7 out of 7 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The newest entry dates from 21 June 2022: an open-market purchase of €741, in Chemomab Therapeutics Ltd. The median gap between a trade and its publication by SEC (Form 4) is 7 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Donald Marvin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 250 shares@ US$3.300.0063% mcap45.1% of flowAmerican Depositary SharesSEC:0001178913-22-002402:0Canonical exit: 14 Jun 2022 (T+90)
- 250 shares@ US$4.0054.9% of flowAmerican Depositary SharesSEC:0001178913-22-001179:0Canonical exit: 12 Jun 2022 (T+90)
2 of 2 declarations
